Condition: Lung Cancer (Diagnosis) · Nodule, Solitary Pulmonary · Sponsor: Herlev and Gentofte Hospital
The goal of the NIMBLE study is to evaluate blood-based biomarkers for lung cancer risk prediction in patients referred with a lung nodule. Each blood biomarker will be evaluated for descriminating malignant from benign lung nodules alone and in combination with other blood biomarkers, patient characteristics and radiological features.
This description comes directly from the study's public registry record.
Søren Egstrand, MD, PhD · 0045 21682147 · soeren.egstrand@regionh.dk
Always discuss trial participation with your own doctor first.
| Gentofte Hospital | Gentofte Municipality, Denmark | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07623473